Back to search

The University of Edinburgh

Genetic basis of previously unexplained aniridia

Abstract

dc:description.abstract

Classical aniridia [MIM 106210] is a rare, panocular malformation characterised by a spectrum of iris and foveal hypoplasia, later complicated by cataracts, lens subluxation, glaucoma and keratopathy. It is overwhelmingly associated with PAX6 [MIM 607108] haploinsufficiency. PAX6 is a highly-conserved transcription factor that orchestrates eye development. Whilst the molecular genetic basis of aniridia and PAX6 disruption is broadly known, there remain unexplained areas that have guided the work in this thesis. PAX6 missense variants can partially or fully phenocopy haploinsufficiency, causing classical aniridia. Why they also cause rare “worse than null” phenotypes is unclear. In order to study the effect of variant class on phenotype, I performed systematic, detailed ocular phenotyping followed by cluster analysis of PAX6 eye malformations. This compared all available missense variant cases (n=161) with a size-matched control of likely gene-disruptive (LGD) cases. Whilst LGD variants were almost universally associated with classical aniridia, the phenotypic spectrum of missense cases was wider and appeared to cluster separately, ranging in severity from isolated foveal hypoplasia (hypomorphic) to bilateral severe microphthalmia (worse than null). Recurrent substitutions of key residues in the DNA-binding paired domain of PAX6 accounted for the most severe cases, notably p.Ser54Arg and p.Asn124Lys. The impact of these variants was investigated in vitro, studying the binding of purified PAX6 paired domain to well-characterised PAX6 DNA targets, the LE9 and SIMO enhancers. Electromobility shift assays showed that binding was altered by p.Ser54Arg and p.Asn124Lys compared to wild type, though (unlike classical aniridia variants) not totally abrogated. Their impact differed between the two DNA targets studied. Whilst not explaining all of the observed genotype-phenotype correlation, these data suggest that the variants do alter protein-DNA interactions - consistent with results of protein modelling - and could affect the stoichiometry of PAX6 target gene activation. I noted a striking similarity between the rare, severe PAX6 missense cases above and those seen in six families with heterozygous variants in MAB21L1 [MIM 601280], all resulting in Arg51 and Phe52 substitutions. All had aniridia and/or microphthalmia, 3/6 had both, and 2/6 had anomalous optic discs. MAB21L1 is involved in eye development downstream of PAX6, but was not known to cause aniridia. To characterise this further, ocular phenotyping of a CRIPSR-Cas9 gene-edited mouse strain carrying Mab21l1 p.Arg51Leu was performed. Adult mice heterozygous for this allele had a highly-penetrant excavated optic nerve anomaly. The phenotype overlaps with but is milder than the human counterpart. The homozygous animals showed severe microphthalmia. There are still questions to be answered regarding the mechanisms in both human and mouse, which may differ, but the human genetic data strongly support this being a new aniridia-associated gene with a gain of function effect. A small proportion of aniridia is still genetically uncharacterised, indicating that there could be novel ways of inactivating PAX6 or additional disease loci. To address this, I undertook analysis of 37 unrelated mutation-negative individuals with classical aniridia (n=51 including relatives) using paired-end, short-read whole genome sequencing (WGS) technology. Following an in-house analysis pipeline, causative variants were identified in 22/37 cases (60%). 15/22 were structural variants, including: chromosome 11 inversions, one separating PAX6 from its critical downstream enhancers; deletions of this downstream enhancer region; whole/partial gene deletions of PAX6, and lastly three FOXC1 gene deletions. The remainder were intragenic PAX6 single nucleotide variants, including two deep intronic splice variants. RT-PCR analysis of RNA from patient-derived lymphoblastoid cell lines was performed in a subset, confirming missplicing in vitro. Notwithstanding historical differences in PAX6 screening, it is remarkable that over half the cohort had a disease mechanism involving either PAX6 or its regulatory region, highlighting the unusually strong disease-gene link. In summary, this thesis fills gaps in our understanding of aniridia genetics through whole genome diagnosis of unsolved cases, underlining the importance of the wider PAX6 locus and adding to the known variants which inactivate it, as well as through characterisation of severe aniridia-microphthalmia phenotypes caused by rare missense variants in PAX6 and in the novel aniridia-associated gene MAB21L1.

Degree

thesis:*
Grantor dc:publisher
The University of Edinburgh
Year dc:date.issued
2025

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Hall, Hildegard Nikki
Advisors dc:contributor.advisor
  • Bickmore, Wendy
  • Rainger, Joe

Subjects

dc:subject × 5

Rights

Language dc:language.iso
en

Identifiers

dc:identifier.*

Chain of custody

source
Harvested from
University of Edinburgh
Base URL
era.ed.ac.uk/server/oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Hall, Hildegard Nikki. Genetic basis of previously unexplained aniridia. The University of Edinburgh, 2025. https://hdl.handle.net/1842/44167